BR112018001387B8 - Composição de absorção percutânea, e, emplastro tipo matriz - Google Patents

Composição de absorção percutânea, e, emplastro tipo matriz

Info

Publication number
BR112018001387B8
BR112018001387B8 BR112018001387A BR112018001387A BR112018001387B8 BR 112018001387 B8 BR112018001387 B8 BR 112018001387B8 BR 112018001387 A BR112018001387 A BR 112018001387A BR 112018001387 A BR112018001387 A BR 112018001387A BR 112018001387 B8 BR112018001387 B8 BR 112018001387B8
Authority
BR
Brazil
Prior art keywords
absorption composition
matrix
basic
sorbic acid
percutaneous absorption
Prior art date
Application number
BR112018001387A
Other languages
English (en)
Other versions
BR112018001387A2 (pt
BR112018001387B1 (pt
Inventor
Hidetoshi Hamamoto
Naoya AKAZAWA
Yasushi Miwa
Original Assignee
Medrx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medrx Co Ltd filed Critical Medrx Co Ltd
Publication of BR112018001387A2 publication Critical patent/BR112018001387A2/pt
Publication of BR112018001387B1 publication Critical patent/BR112018001387B1/pt
Publication of BR112018001387B8 publication Critical patent/BR112018001387B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição de absorção percutânea, e, emplastro tipo matriz. o objetivo da presente invenção é fornecer: uma composição de absorção transdérmica tendo propriedades melhoradas de penetração do fármaco básico na pele; e um acelerador de absorção transdérmica para um fármaco básico. o objetivo pode ser alcançado por uma composição de absorção transdérmica compreendendo um fármaco básico ou um sal do mesmo e ácido sórbico e/ou um sal metálico de ácido sórbico. é preferido que o teor do componente de ácido sórbico seja de 0,5 a 2,5 mols com relação a 1 mol do fármaco básico. também é preferido que a composição de acordo com a presente invenção contenha adicionalmente um composto básico orgânico e/ou um componente básico inorgânico.
BR112018001387A 2015-08-29 2016-08-29 Composição de absorção percutânea, e, emplastro tipo matriz BR112018001387B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPPCT/JP2015/074553 2015-08-29
PCT/JP2015/074553 WO2017037813A1 (ja) 2015-08-29 2015-08-29 塩基性薬物とソルビン酸とを含有する経皮吸収組成物
PCT/JP2016/075203 WO2017038767A1 (ja) 2015-08-29 2016-08-29 経皮吸収組成物

Publications (3)

Publication Number Publication Date
BR112018001387A2 BR112018001387A2 (pt) 2018-09-11
BR112018001387B1 BR112018001387B1 (pt) 2023-09-05
BR112018001387B8 true BR112018001387B8 (pt) 2024-03-05

Family

ID=58187853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001387A BR112018001387B8 (pt) 2015-08-29 2016-08-29 Composição de absorção percutânea, e, emplastro tipo matriz

Country Status (15)

Country Link
EP (1) EP3342423B1 (pt)
JP (2) JP6259117B2 (pt)
KR (1) KR20180039622A (pt)
CN (1) CN107427509B (pt)
BR (1) BR112018001387B8 (pt)
CO (1) CO2018001831A2 (pt)
ES (1) ES2864017T3 (pt)
MX (1) MX2018002015A (pt)
MY (1) MY189987A (pt)
PH (1) PH12018500271A1 (pt)
RU (1) RU2702356C2 (pt)
SG (1) SG11201800043UA (pt)
UA (1) UA123212C2 (pt)
WO (2) WO2017037813A1 (pt)
ZA (1) ZA201800296B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019151423A1 (ja) * 2018-01-31 2019-08-08 株式会社 メドレックス チザニジン治療システム
TWI772807B (zh) * 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
WO2023062201A1 (en) * 2021-10-15 2023-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of tizanidine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61172830A (ja) * 1985-01-26 1986-08-04 Showa Denko Kk 皮膚外用剤組成物
US20040142024A1 (en) * 1999-07-27 2004-07-22 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use
DE60034458T2 (de) * 1999-07-27 2008-01-03 Hisamitsu Pharmaceutical Co., Inc., Tosu Pflaster zur äusserlichen anwendung
AU2005224182B2 (en) * 2004-03-19 2008-04-17 Mcneil Ab Means for transdermal administration of nicotine
JP4807974B2 (ja) * 2005-06-30 2011-11-02 帝國製薬株式会社 経皮吸収促進組成物
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101143127A (zh) * 2007-10-25 2008-03-19 复旦大学 一种酚妥拉明外用制剂及其制备方法
JP5333972B2 (ja) * 2007-11-22 2013-11-06 株式会社 メドレックス 脂肪酸系イオン液体を有効成分とする外用剤組成物
WO2009107477A1 (ja) * 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
RU2543639C2 (ru) * 2009-09-07 2015-03-10 Нипро Пэтч Ко., Лтд. Чрескожно всасывающийся препарат
CA2797320A1 (en) * 2010-06-18 2011-12-22 Merz Pharma Gmbh & Co. Kgaa Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
CN110693859A (zh) * 2012-06-20 2020-01-17 美德阿利克斯株式会社 通过掺混药物、有机溶剂、亲脂性基质和粉末获得的粘附制剂组合物

Also Published As

Publication number Publication date
RU2702356C2 (ru) 2019-10-08
BR112018001387A2 (pt) 2018-09-11
BR112018001387B1 (pt) 2023-09-05
SG11201800043UA (en) 2018-02-27
JP6259117B2 (ja) 2018-01-10
RU2018110617A3 (pt) 2019-09-30
ES2864017T3 (es) 2021-10-13
ZA201800296B (en) 2019-04-24
RU2018110617A (ru) 2019-09-30
MX2018002015A (es) 2018-06-19
JP2017149782A (ja) 2017-08-31
CO2018001831A2 (es) 2018-05-21
WO2017037813A1 (ja) 2017-03-09
JPWO2017038767A1 (ja) 2017-09-07
PH12018500271A1 (en) 2018-08-13
MY189987A (en) 2022-03-22
EP3342423A1 (en) 2018-07-04
CN107427509B (zh) 2021-06-15
UA123212C2 (uk) 2021-03-03
WO2017038767A1 (ja) 2017-03-09
EP3342423A4 (en) 2018-07-25
KR20180039622A (ko) 2018-04-18
CN107427509A (zh) 2017-12-01
EP3342423B1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
BR112016013299A2 (pt) Composto
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112018016724A2 (pt) composto de pirimidina condensado ou sal do mesmo
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015009806A2 (pt) composições adjuvantes aquosas
BR112015023986A2 (pt) dispositivo de aplicação e processo para a maquilagem e/ou o cuidado para os lábios
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112015004968A2 (pt) combinações de compostos ativos
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112017004925A2 (pt) composição e método
BR112016007509A2 (pt) composição antitranspirante melhorada
BR112018001387B8 (pt) Composição de absorção percutânea, e, emplastro tipo matriz
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112015017465A2 (pt) composição de óleo para prevenção de ferrugem
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
BR112018074755A2 (pt) composição líquida não oleosa, não aquosa, e, métodos para controle de pragas e para melhorar o crescimento das plantas.
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
BR112015006738A2 (pt) terapia de combinação usando belinostat e trabectedina
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/08/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2748 DE 05/09/2023, QUANTO AO ITEM (72) NOME DO INVENTOR.